Skip to main content
. 2023 May 22. Online ahead of print. doi: 10.1016/j.transproceed.2023.05.007

Table 2.

Alterations to Immunosuppressive Agents, Segmented by Total Drug Suspension or Dose Reduction

Characteristic N Overall
N = 234*
Survived
N = 186*
Dead
N = 48*
P Value
TAC Reduction 194 31 (16%) 22 (14%) 9 (22%) .2
TAC Suspension 194 30 (15%) 14 (9.1%) 16 (40%) < .001
MFS Reduction 138 6 (4.3%) 4 (3.9%) 2 (5.7%) .6
MFS Suspension 138 70 (51%) 48 (47%) 22 (63%) .10
EVR Reduction 42 0 (0%) 0 (0%) 0 (0%) -
EVR Suspension 42 8 (19%) 6 (18%) 2 (25%) .6
PRED Reduction 18 0 (0%) 0 (0%) 0 (0%) -
PRED Suspension 18 3 (17%) 0 (0%) 3 (50%) .025
AZA Reduction 5 0 (0%) 0 (0%) 0 (0%) -
AZA Suspension 5 3 (60%) 1 (33%) 2 (100%) .4
CsA Reduction 10 0 (0%) 0 (0%) 0 (NA%) -
CsA Suspension 10 4 (40%) 4 (40%) 0 (NA%) > .9
Any partial or total supension to Imunossupression 222 121 (55%) 84 (48%) 37 (80%) < .001

Values are displayed as “count (percent).”Bolded = significance (p > 0.05).

AZA = Azathioprine; CsA = Cyclosporine A; EVR = Everolimus; MFS = Mycophenolate Sodium; PRED = Prednisone; Tac = Tacrolimus.

n (%).

Pearson's χ2 test test; Fisher's exact test.